CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma-Reference-Cited by-同舟云学术

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma

Published:2021-02-05 Issue:6 Volume:10 Page:2013-2025
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Nishikawa Masahiro¹,Inoue Akihiro¹^ORCID,Ohnishi Takanori²,Yano Hajime³,Kanemura Yonehiro⁴⁵,Kohno Shohei¹,Ohue Shiro⁶,Ozaki Saya¹,Matsumoto Shirabe¹,Suehiro Satoshi¹,Nakamura Yawara¹,Shigekawa Seiji¹,Watanabe Hideaki¹,Kitazawa Riko⁷,Tanaka Junya³,Kunieda Takeharu¹

Affiliation:

1. Department of Neurosurgery Ehime University School of Medicine Toon Japan

2. Department of Neurosurgery Washoukai Sadamoto Hospital Matsuyama Japan

3. Department of Molecular and Cellular Physiology Ehime University School of Medicine Toon Japan

4. Department of Biomedical Research and Innovation Institute for Clinical Research National Hospital Organization Osaka National Hospital Osaka Japan

5. Department of Neurosurgery National Hospital Organization Osaka National Hospital Osaka Japan

6. Department of Neurosurgery Ehime Prefectural Central Hospital Matsuyama Japan

7. Division of Diagnostic Pathology Ehime University Hospital Toon Japan

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3767

Reference35 articles.

1. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

2. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma